At TNeuroPharma, we believe that there’s always another way to look at a problem to find a solution. We believe that in the complex area of neurodegenerative diseases, an earlier definitive diagnosis could be the root for understanding -- and the key to moving forward.Most importantly, we believe that effective treatments for Alzheimer’s disease and other neurodegenerative disorders are within our reach. And our goal is to assist and support today’s pharmaceutical companies reach the milestone the world has been waiting for when it comes to drug development for Alzheimer’s and other neurodegenerative diseases.With TNeuroPharma’s technology and patented biomarker kit, pharmaceutical companies can, for the first time, identify patients with confirmed Alzheimer’s disease to study in their clinical trials – two steps ahead of anything that is being used to detect AD so far. By working with confirmed AD patients rather than waiting for a definitive diagnosis upon autopsy, pharmaceutical companies can see if their drug is work in real time -- saving hundreds of millions of dollars and decades of time in the development of effective treatments for Alzheimer’s disease. Most importantly, though, the world can have new hope when it comes to overcoming the many challenges presented by this complex disease.

StemVax Therapeutics is a Translational Biotechnology Company that develops novel therapies for brain tumor patients. We focus our efforts on developing immunotherapeutic approaches to treating patients with Glioblastoma (formerly Glioblastoma Multiforme; GBM), a devastating brain cancer. We also focus our research efforts on novel drug development to target Cancer Stem cells and other multi-resistant cancer cells.

Oversaw clinical lab operations, directed basic biomedical research program, taught graduate students and researchers.

SU School of Medicine, Div. of Immunology: NIH/SU Cancer Biology Fellow, NIH/SU Immunology Fellow, Leukemia Society of America Fellow and Special Fellow. Conducted and published independent research on function of the immune (T) cell co-receptor, CD8ab.

Doctoral student in Dept. of Molecular & Cellular Biology, Division of Immunology (formerly Dept. of Microbiology & Immunology). Team-taught didactic lecture and laboratory courses; conducted and published independent research on functional genetic diversity within immune receptor genes (MHC class I).